Skip to main content

Table 2 TGFBR2 and IL12B SNPs associated with overall survival ( P -value <0.001) in ER-negative patients with chemotherapy

From: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

Chr Gene SNP Minor allele MAF ER-negative patients who received adjuvant chemotherapy ER-negative patients who did not receive adjuvant chemotherapy ER-positive patients who received adjuvant chemotherapy
Cases, number Events, number HR a (95% CI) P -value Cases, number Events, number HR a (95% CI) P -value P heterogeneity b Cases, number Events, number HR a (95% CI) P -value P heterogeneity c
3 TGFBR2 rs1367610 C 0.14 1499 267 1.54 (1.22, 1.95) 3.08 × 10−4 834 155 0.78 (0.55, 1.13) 0.191 8.82 × 10−4 3151 376 0.88 (0.70, 1.10) 0.251 2.62 × 10−4
5 IL12B rs2546892 A 0.17 1499 267 1.50 (1.21, 1.86) 1.81 × 10−4 835 155 0.99 (0.74, 1.33) 0.968 0.025 3151 376 0.99 (0.82, 1.20) 0.940 4.63 × 10−3
5 IL12B rs2853694 C 0.51 1499 267 0.73 (0.61, 0.87) 3.67 × 10−4 835 155 1.06 (0.85, 1.33) 0.596 0.020 3151 376 0.95 (0.82, 1.10) 0.529 0.023
  1. aHR adjusted for age of diagnosis, tumor size, tumor grade, node status and nine principal components to account for population substructure and stratified by study. b P-value for test of heterogeneity between ER-negative breast cancer patients who received adjuvant chemotherapy and ER-negative breast cancer patients who did not receive adjuvant chemotherapy. c P-value for test of heterogeneity between ER-negative breast cancer patients who received adjuvant chemotherapy and ER-positive breast cancer patients who received adjuvant chemotherapy. TGFBR2, transforming growth factor, beta receptor II; SNP, single nucleotide polymorphism; ER, estrogen receptor; Chr, chromosome; MAF, minor allele frequency; HR, hazard ratio; IL12B, interleukin 12B; and CI, confidence interval.